Abbott (NYSE: ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the ...
Abbott (NYSE: ABT) today announced new clinical data supporting its minimally invasive therapies for treating AFib.
A research team led by the Department of Medicine, under the School of Clinical Medicine, LKS Faculty of Medicine of the ...
Johnson & Johnson MedTech (NYSE:JNJ) today announced 12-month pilot data from a study of its investigational Omnypulse ...
Shares of Pulse Biosciences shot higher after the company reported positive results from its first-in-human feasibility study for its cardiac catheter system to treat atrial fibrillation, a form of ...
10hon MSN
Study finds 90 minutes weekly activity after ablation linked to fewer atrial fibrillation relapses
New research from CU Anschutz scientists suggests that staying physically active after heart rhythm treatment may ...
Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation ...
A new multi-country European study demonstrates that pulsed field ablation (PFA) using the Farapulse system delivers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results